Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gusongbao + rosa roxburghii is a combination product consisting of "Gusongbao" (骨松宝), a traditional Chinese medicine formulation, and "rosa roxburghii" (刺梨), also known as chestnut rose. This combination is being studied for its potential therapeutic effects, particularly in the treatment of endemic fluorosis (地方性氟中毒). Gusongbao itself is available as capsules or granules and is produced by Guizhou Fuhua Pharmaceutical. Rosa roxburghii is rich in vitamin C and polyphenols and has been used in functional foods and supplements for its antioxidant properties. The mechanism of action for this combination likely involves bone metabolism modulation from Gusongbao components alongside antioxidative and anti-inflammatory effects from rosa roxburghii. Research into this specific combination focuses on synergistic benefits for bone health and detoxification related to fluoride exposure[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gusongbao + rosa roxburghii.